Candel Therapeutics (CADL) Change in Cash (2020 - 2025)

Candel Therapeutics has disclosed Change in Cash across 6 years of filings, most recently posting $32.9 million for Q4 2025.

• Change in Cash for Q4 2025 came in at $32.9 million, down 61.77% year-over-year; the trailing twelve-month figure through Dec 2025 was $17.2 million (down 74.38% YoY), and the FY2025 annual result was $17.2 million, down 74.38% from the prior year.
• Change in Cash came in at $32.9 million for Q4 2025 at Candel Therapeutics, up from -$13.7 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $86.1 million in Q4 2024 to a low of -$18.4 million in Q4 2022.
• The 5-year median for Change in Cash is -$5.7 million (2021), against an average of $4.2 million.
• Across the five-year window, Change in Cash surged 2964.06% in 2021 and plunged 645.02% in 2023, its largest moves.
• Candel Therapeutics' Change in Cash stood at -$5.7 million in 2021, then plunged by 219.73% to -$18.4 million in 2022, then surged by 58.77% to -$7.6 million in 2023, then soared by 1237.33% to $86.1 million in 2024, then slumped by 61.77% to $32.9 million in 2025.
• The last three Change in Cash figures came in at $32.9 million (Q4 2025), -$13.7 million (Q3 2025), and $8.5 million (Q2 2025), per Business Quant data.